Detalhe da pesquisa
1.
Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection.
J Infect Dis
; 227(11): 1303-1312, 2023 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484441
2.
Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.
J Infect Dis
; 222(6): 948-956, 2020 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32161969
3.
Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women.
Sex Transm Dis
; 46(10): 663-669, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31464859
4.
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
Int J Cancer
; 142(12): 2491-2500, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29377141
5.
Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Int J Cancer
; 142(5): 949-958, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055031
6.
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Int J Cancer
; 143(9): 2299-2310, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29845626
7.
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
Int J Cancer
; 138(10): 2428-38, 2016 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26685704
8.
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Int J Cancer
; 139(12): 2812-2826, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27541373
9.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Lancet Oncol
; 16(7): 775-86, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26071347
10.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Lancet
; 384(9961): 2213-27, 2014 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25189358
11.
Efficacy results of a trial of a herpes simplex vaccine.
N Engl J Med
; 366(1): 34-43, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22216840
12.
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.
J Infect Dis
; 210(4): 545-57, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24652494
13.
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
J Infect Dis
; 210(4): 517-34, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24610876
14.
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.
BMC Infect Dis
; 14: 551, 2014 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25927224
15.
Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme.
Pharmacoepidemiol Drug Saf
; 23(5): 466-79, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24644063
16.
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
J Infect Dis
; 208(9): 1391-6, 2013 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24092907
17.
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.
Clin Infect Dis
; 56(3): 344-51, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23087395
18.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol
; 13(1): 100-10, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22075170
19.
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol
; 13(1): 89-99, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22075171
20.
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
Int J Cancer
; 131(12): 2832-8, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22492244